1. Protein Tyrosine Kinase/RTK Apoptosis Autophagy
  2. Src Bcr-Abl Apoptosis Autophagy
  3. Dasatinib

Dasatinib (BMS-354825) (GMP) is a GMP-grade Dasatinib (HY-10181). GMP-grade small molecules can be used as adjuvant agents in cell therapy. Dasatinib (BMS-354825) is an orally active, ATP-competitive, dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Ki values ​​for Src and Bcr-Abl are 16 pM and 30 pM, respectively. Dasatinib inhibits Bcr-Abl and Src with IC50 values ​​of less than 1.0 nM and 0.5 nM, respectively. Dasatinib also induces apoptosis and autophagy.

For research use only. We do not sell to patients.

Dasatinib

Dasatinib Chemical Structure

CAS No. : 302962-49-8

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Dasatinib:

Other Forms of Dasatinib:

Top Publications Citing Use of Products

View All Src Isoform Specific Products:

View All Bcr-Abl Isoform Specific Products:

  • Biological Activity

  • References

  • Customer Review

Description

Dasatinib (BMS-354825) (GMP) is a GMP-grade Dasatinib (HY-10181). GMP-grade small molecules can be used as adjuvant agents in cell therapy. Dasatinib (BMS-354825) is an orally active, ATP-competitive, dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Ki values ​​for Src and Bcr-Abl are 16 pM and 30 pM, respectively. Dasatinib inhibits Bcr-Abl and Src with IC50 values ​​of less than 1.0 nM and 0.5 nM, respectively. Dasatinib also induces apoptosis and autophagy[1].

Cellular Effect
Cell Line Type Value Description References
A549 IC50
2.55 μM
Compound: Dasatinib
Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay
[PMID: 38171149]
ASPC1 IC50
3.3 μM
Compound: Dasatinib
Cytotoxicity against human ASPC1 cells harboring KRAS G12D mutant assessed as inhibition of cell growth
Cytotoxicity against human ASPC1 cells harboring KRAS G12D mutant assessed as inhibition of cell growth
[PMID: 38848113]
B16-F10 IC50
0.74 μM
Compound: Dasatinib
Synergistic photodynamic antitumor activity against mouse B16-F10 cells assessed as inhibition of cell proliferation incubated for 48 hrs under 10 J/cm2 light irradiation at 660 nm in presence of chlorin e6 by CCK-8 assay
Synergistic photodynamic antitumor activity against mouse B16-F10 cells assessed as inhibition of cell proliferation incubated for 48 hrs under 10 J/cm2 light irradiation at 660 nm in presence of chlorin e6 by CCK-8 assay
[PMID: 37690263]
B16-F10 IC50
13.5 μM
Compound: Dasatinib
Synergistic photodynamic antitumor activity against mouse B16-F10 cells assessed as inhibition of cell proliferation incubated for 48 hrs under dark condition in presence of chlorin e6 by CCK-8 assay
Synergistic photodynamic antitumor activity against mouse B16-F10 cells assessed as inhibition of cell proliferation incubated for 48 hrs under dark condition in presence of chlorin e6 by CCK-8 assay
[PMID: 37690263]
B16-F10 IC50
16.42 μM
Compound: Dasatinib
Cytotoxicity against mouse B16-F10 cells incubated for 48 hrs under dark condition by CCK-8 assay
Cytotoxicity against mouse B16-F10 cells incubated for 48 hrs under dark condition by CCK-8 assay
[PMID: 37690263]
BaF3 IC50
0.3 nM
Compound: Dasatinib
Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 Q252H mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 Q252H mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
[PMID: 21481795]
BaF3 IC50
0.4 nM
Compound: Dasatinib
Antiproliferative activity against native mouse BaF3 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
Antiproliferative activity against native mouse BaF3 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
[PMID: 21481795]
BaF3 IC50
1 nM
Compound: Dasatinib
Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 Y253H mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 Y253H mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
[PMID: 21481795]
BaF3 IC50
1.1 nM
Compound: Dasatinib
Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 M351T mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 M351T mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
[PMID: 21481795]
BaF3 IC50
1.2 nM
Compound: Dasatinib
Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 H396P mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 H396P mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
[PMID: 21481795]
BaF3 IC50
2 nM
Compound: Dasatinib
Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 E255V mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 E255V mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
[PMID: 21481795]
BaF3 IC50
2 nM
Compound: Dasatinib
Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 Y253F mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 Y253F mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
[PMID: 21481795]
BaF3 IC50
2.3 nM
Compound: Dasatinib
Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 F317L mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 F317L mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
[PMID: 21481795]
BaF3 IC50
2.7 nM
Compound: Dasatinib
Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 F359C mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 F359C mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
[PMID: 21481795]
BaF3 IC50
2.8 nM
Compound: Dasatinib
Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 G250E mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 G250E mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
[PMID: 21481795]
BaF3 IC50
3800 nM
Compound: Dasatinib
Antiproliferative activity against parent mouse BaF3 cells assessed as inhibition of cell proliferation measured after 72 hrs in presence of IL-3 by MTT assay
Antiproliferative activity against parent mouse BaF3 cells assessed as inhibition of cell proliferation measured after 72 hrs in presence of IL-3 by MTT assay
[PMID: 21481795]
BaF3 IC50
5200 nM
Compound: Dasatinib
Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 T315I mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 T315I mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
[PMID: 21481795]
BaF3 IC50
65 nM
Compound: Dasatinib
Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 T315A mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 T315A mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
[PMID: 21481795]
BaF3 IC50
7.3 nM
Compound: Dasatinib
Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 L248R mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 L248R mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
[PMID: 21481795]
BaF3 IC50
8 nM
Compound: Dasatinib
Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 E255K mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 E255K mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
[PMID: 21481795]
BaF3 IC50
8 nM
Compound: Dasatinib
Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 V299L mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
Antiproliferative activity against mouse BaF3 cells harbouring BCR-ABL1 V299L mutant assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
[PMID: 21481795]
BaF3 IC50
> 200 nM
Compound: Chemical probe: BMS-354825
Cytotoxicity against mouse BaF3 cells assessed as reduction in cell proliferation incubated for 72 hrs by methane-thiosulfonate-based CellTiter96 viability analysis
Cytotoxicity against mouse BaF3 cells assessed as reduction in cell proliferation incubated for 72 hrs by methane-thiosulfonate-based CellTiter96 viability analysis
[PMID: 15930265]
Hep 3B2 GI50
86 nM
Compound: Dasatinib
Growth inhibition of human Hep3B cells after 3 days by MTT assay
Growth inhibition of human Hep3B cells after 3 days by MTT assay
[PMID: 18979199]
HepG2 GI50
> 50000 nM
Compound: Dasatinib
Growth inhibition of human HepG2 cells after 3 days by MTT assay
Growth inhibition of human HepG2 cells after 3 days by MTT assay
[PMID: 18979199]
HepG2 IC50
1.01 μM
Compound: Dasatinib
Synergistic photodynamic antitumor activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 48 hrs under 10 J/cm2 light irradiation at 660 nm in presence of chlorin e6 by CCK-8 assay
Synergistic photodynamic antitumor activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 48 hrs under 10 J/cm2 light irradiation at 660 nm in presence of chlorin e6 by CCK-8 assay
[PMID: 37690263]
HepG2 IC50
18.2 μM
Compound: Dasatinib
Cytotoxicity against human HepG2 cells incubated for 48 hrs under dark condition by CCK-8 assay
Cytotoxicity against human HepG2 cells incubated for 48 hrs under dark condition by CCK-8 assay
[PMID: 37690263]
HepG2 IC50
74.75 μM
Compound: Dasatinib
Synergistic photodynamic antitumor activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 48 hrs under dark condition in presence of chlorin e6 by CCK-8 assay
Synergistic photodynamic antitumor activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 48 hrs under dark condition in presence of chlorin e6 by CCK-8 assay
[PMID: 37690263]
Huh-7 GI50
1972 nM
Compound: Dasatinib
Growth inhibition of human Huh-7 cells after 3 days by MTT assay
Growth inhibition of human Huh-7 cells after 3 days by MTT assay
[PMID: 18979199]
MCF7 IC50
> 10 μM
Compound: Dasatinib
Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth
Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth
[PMID: 38848113]
MDA-MB-231 IC50
0.157 μM
Compound: Dasatinib
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay
[PMID: 38070430]
NCI-H1975 IC50
1.26 μM
Compound: Dasatinib
Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTT assay
[PMID: 38171149]
PLC-PRF-5 GI50
15 nM
Compound: Dasatinib
Growth inhibition of human PLC-PRF-5 cells after 3 days by MTT assay
Growth inhibition of human PLC-PRF-5 cells after 3 days by MTT assay
[PMID: 18979199]
Vero C1008 EC50
5.4 μM
Compound: Dasatinib
Antiviral activity against MERS-CoV infected in african green monkey Vero E6
Antiviral activity against MERS-CoV infected in african green monkey Vero E6
[PMID: 37597435]
In Vitro

Dasatinib demonstrates significant activity against Bcr-Abl, Src, Lck, Yes, c-Kit, PDGFRβ, p38, Her1, Her2, FGFR-1, and MEK with IC50s of <1.0, 0.50, 0.40, 0.50, 5.0, 28, 100, 180, 720, 880, and 1700 nM, respectively[1].
Dasatinib shows antiproliferative activities aversus K562 chronic myelogenous leukemia (CML), PC3 human prostate tumor, MDA-MB-231 human breast tumor, and WiDr human colon tumor cell lines with IC50s of <1.0 nM, 9.4 nM, 12 nM, and 52 nM, respectively[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Dasatinib (5 mg/kg and 50 mg/kg, qd×10d, 5 on-2 off) possesses potent antitumor activity and a high safety margin in a K562 xenograft model of chronic myelogenous leukemia (CML), demonstrating complete tumor regressions and low toxicity at multiple dose levels[1].
Dasatinib (10 mg/kg) has a pharmacokinetic profile appropriate for continued advancement into in vivo efficacy studies. Dasatinib (10 mg/kg) demonstrates favorable half-lives (t1/2s) of 3.3 and 3.1 h for i.v. and oral, respectively. The oral bioavailability (Fpo) in this study is 27%[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

488.01

Formula

C22H26ClN7O2S

CAS No.
SMILES

O=C(C1=CN=C(S1)NC2=NC(C)=NC(N3CCN(CC3)CCO)=C2)NC4=C(C=CC=C4Cl)C

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Dasatinib
Cat. No.:
HY-10181G
Quantity:
MCE Japan Authorized Agent: